688506:SSESichuan Biokin Pharmaceutical Co., Ltd. Class A Analysis

Sichuan Biokin Pharmaceutical is trading at CNY 237, well below its 20‑day (CNY 261), 50‑day (CNY 277) and 200‑day (CNY 319) simple moving averages, signaling a sustained bearish bias. The RSI of 31.6 indicates oversold conditions, yet the MACD remains bearish with a negative histogram, and the price sits just above the technical support level of CNY 228.2 while facing a distant resistance near CNY 292.2. Volatility is high at 35.8 % over the past 30 days, but beta is near zero (0.03), suggesting limited market‑wide price swing risk. Fundamentally, the company posted a robust 40 % revenue growth and an impressive gross margin of 89.5 %, but operating and net margins are negative (‑8 % and ‑0.5 % respectively), with EBITDA and cash flows deeply in the red. Despite a sizable cash pile (CNY 5.0 bn) that exceeds debt (CNY 3.25 bn), the negative free cash flow and a high price‑to‑book (17.3×) and price‑to‑sales (38.4×) ratio point to an overvalued valuation. The “Extreme Greed” sentiment (91.05) adds a cautionary note as investors may be over‑optimistic amid these mixed signals.